Soligenix Inc. (NASDAQ:SNGX) — Market Cap & Net Worth
Market Cap & Net Worth: Soligenix Inc. (SNGX)
Soligenix Inc. (NASDAQ:SNGX) has a market capitalization of $3.63 Million ($3.63 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29264 globally and #5978 in its home market, demonstrating a -4.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Soligenix Inc.'s stock price $0.36 by its total outstanding shares 10086130 (10.09 Million). Also see Soligenix Inc. balance sheet assets for a full breakdown of the balance sheet.
Soligenix Inc. Market Cap History: 2015 to 2026
Soligenix Inc.'s market capitalization history from 2015 to 2026. Data shows change from $27.35 Billion to $3.63 Million (-55.85% CAGR). Also see Soligenix Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Soligenix Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #848 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2722 of 3165 |
Weight: Soligenix Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Soligenix Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Soligenix Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Soligenix Inc. stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
227.71x
Soligenix Inc.'s market cap is 227.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $27.35 Billion | $8.77 Million | -$7.83 Million | 3119.71x | N/A |
| 2016 | $5.45 Billion | $10.45 Million | -$3.25 Million | 521.25x | N/A |
| 2017 | $5.37 Billion | $5.43 Million | -$7.15 Million | 989.08x | N/A |
| 2018 | $2.08 Billion | $5.24 Million | -$8.90 Million | 397.21x | N/A |
| 2019 | $3.51 Billion | $3.22 Million | -$9.36 Million | 1091.53x | N/A |
| 2020 | $3.10 Billion | $1.93 Million | -$17.69 Million | 1604.98x | N/A |
| 2021 | $1.60 Billion | $33.35K | -$12.55 Million | 47925.68x | N/A |
| 2022 | $1.09 Billion | $250.00K | -$13.80 Million | 4376.57x | N/A |
| 2023 | $122.20 Million | $839.36K | -$6.14 Million | 145.58x | N/A |
| 2024 | $27.18 Million | $119.37K | -$8.27 Million | 227.71x | N/A |
Competitor Companies of SNGX by Market Capitalization
Companies near Soligenix Inc. in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Soligenix Inc. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Soligenix Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Soligenix Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Soligenix Inc.'s market cap moved from $27.35 Billion to $ 3.63 Million, with a yearly change of -55.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.63 Million | -73.13% |
| 2025 | $13.52 Million | -50.28% |
| 2024 | $27.18 Million | -77.76% |
| 2023 | $122.20 Million | -88.83% |
| 2022 | $1.09 Billion | -31.55% |
| 2021 | $1.60 Billion | -48.41% |
| 2020 | $3.10 Billion | -11.72% |
| 2019 | $3.51 Billion | +68.60% |
| 2018 | $2.08 Billion | -61.25% |
| 2017 | $5.37 Billion | -1.36% |
| 2016 | $5.45 Billion | -80.09% |
| 2015 | $27.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Soligenix Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.63 Million USD |
| MoneyControl | $3.63 Million USD |
| MarketWatch | $3.63 Million USD |
| marketcap.company | $3.63 Million USD |
| Reuters | $3.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more